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Abstract 
A simple, sensitive, reproducible and cost effective reversed-phase liquid chromatography (RPHPLC) 
method coupled with a photodiode array detector was developed and validated for determination of Flucytosine 
and its related substances in pharmaceutical dosage forms, especially for injectable solution. The separation was 
achieved from octadecylsilyl silica gel, C18 (4.6 mm x 250 mm, 5µ) column with a mobile phase consisting of 
HPLC grade Water and Methanol (95:5) at a flow rate of 1ml/min with UV detection at 260 nm at 30
°
C column 
temperature. Total run time was 10 min within which main compound and other known (Fluorouracil) and 
unknown impurities were separated. Stability indicating capability was established by force degradation 
experiments and separation of known degradation products. This chromatographic method was optimized using 
the samples generated from forced degradation studies and the impurity spiked solution. Good resolution 
between the peaks corresponds to process-related impurities and degradation products from the analyte were 
achieved. The method was validated for Accuracy, Repeatability, Reproducibility and Robustness, Linearity, 
LOQ, LOD were established for Flucytosine and its impurities in a single RPHPLC method. Therefore, this 
method can be used as a more convenient and efficient option for the analysis of Flucytosine assay and it’s 
related substances in injectable pharmaceutical dosage form to establish the quality of the drug product during 
routine analysis with consistent and reproducible results. 
Keywords: Injectable pharmaceuticals, reversed-phase liquid chromatography; cytosine deaminase; 5-
fluorocytosine. 
 
1.Introduction 
Flucytosine, a fluorinated pyrimidine 
analogue, is a synthetic antimycotic drug. Chemically 
it is referred to as 4-amino-5-fluoro-2(1H) - 
pyrimidinone. Flucytosine is structured like cytostatic 
fluorouracil and also resembles floxuridine[1][4]. 5-
Fluorocytosine (5-FC; flucytosine) is a 
fluoropyrimidine that is used primarily in the 
management of systemic mycoses, such as 
candidiasis, chromoblastomycosis, cryptococcal 
meningitis, and torulopsosis[14]. 
5-Fluorouracil is used for the treatment of 
different cancer especially for outside layer of the 
adrenal gland, anus, bladder, cervix, endometrium, 
ovaries, esophagus, head and neck, penis, liver, 
prostate, skin, vulva, Carcinoid tumors[14].  
Figure-01: Structure 
 
 
4-amino-5-fluoro-1, 2-dihydropyrimidin-2-one (5-FC) 
 
5-Fluoro-1H, 3H-pyrimidine-2, 4-dione (5-FU) 
 
5- Fluorocytosine is very much stable in 
intravenous solution at regular storing temperatures 
and can therefore be stored at ambient temperatures 
for several years before the critical border of 95% 5-
FC is reached. However, the toxic and teratogen 
degradation product 5-Fluorouracil (Specific 
impurity of 5-FC) may be present in the product, due 
to both impurities in the raw material and the 
formation from 5-FC upon sterilization and 
storage[5]. Identification and quantification of this 
impurity is very much important for pharmaceutical 
dosage forms especially for intravenous infusion. 
Literature survey reveals that there are 
several studies found on determination of Flucytosine 
and also its metabolites in Plasma and other studies 
related to antifungal effect on different 
microorganisms or cultured cells[5][11], but there is 
no sensitive, cost effective, rapid, novel HPLC 
method and validation article to quantify the 
Pharmaceutical dosage forms especially for the 
injectable dosage forms. There is no compendial 
method present right now for injectable 
pharmaceuticals, although, there is method present 
for API or other dosage form but the related 
substances method is under thin layer 
chromatography (TLC) procedure. Related 
substances should be quantified in injectable 
pharmaceuticals which are directly bioavailable in 
the blood serum. Flucytosine produces Fluorouracil 
during sterilization[6]. 5-Fluorocytosine is 
deaminated by cytosine deaminase and produce 5-
Fluorouracil and finally inhibition of protein 
synthesis and DNA synthesis occurred[12]. There is a 
study, which concludes with the suggestion to take 
sharp notice of the amount of the toxic and teratogen 
5-FU in the product[1][6]. Systemic 5-fluorouracil 
can cause a syndrome of delayed myelin destruction 
in the central nervous system[13]. That’s why 
quantification of its degrading products 
(Fluorouracil) is very important during formulation 
of injectable pharmaceutical dosage form. This study 
will confirm to determine Flucytosine and its 
degradents. Though this is a non compendial method 
for intravenous injection, it was validated in 
compliance with ICH Guidelines[15]-[16]. The 
present study describes an HPLC method, with a high 
sensitivity, precision and accuracy for determination 
of Flucytosine and its impurities in injectable 
pharmaceuticals. The objective of the study is to 
outline a easy and cost effective at the same time 
regulatory compliant method by which the 
identification and quantification of Flucytosine and 
its impurities can be introduced. 
 
2. Materials and method 
2.1 Reagents and Chemicals 
All the solvents and chemicals used were of 
HPLC and analytical grade. Milli-Q water and 0.45 
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μm Teflon filter was used throughout the 
experimental work. HPLC grade Methanol from 
(Merck, Germany); Flucytosine USP working 
standard (WS) was obtained from Nantong Jinghua 
Pharmaceutical Co, Ltd., China. Fluorouracil EPCRS 
from EP commission was used. Product development 
batches of Flucytosine IV infusion samples were 
provided as a gift from Square Pharmaceuticals Ltd., 
Bangladesh. Purified water was used for the 
analytical purpose. 
2.2 Instruments  
A Waters alliance, model-e2695 separation 
Module, USA equipped with a Waters 2998 
Photodiode Array Detector (PDA) was used in the 
study. The HPLC method uses a Column: Hichrom 5 
C18, 4.6 x 250 mm, 5µm, Data was recorded by 
using Empower software. Analytical balance from 
Mettler, pH meter from Metrohm, Switzerland, 
Ultrasonic bath from Sonoswiss from Switzerland, 
Water bath from Memmert, Germany were used. 
2.3 Method Development 
2.3.1 Chromatographic conditions 
Different mobile phases were tested in order 
to find the best conditions for the separation of 
Flucytosine in presence of its potential impurity 
(Fluorouracil) and degradation products. The 
optimum composition of mobile phase was 
determined to be Water: Methanol (95:5). 
In this HPLC method, we used 
octadecylsilyl silica gel, C18 (4.6 mm x 250 mm, 5µ) 
column, injection volume 20μl. Detection was carried 
out at 260 nm and the flow rate was 1.0 ml/min and 
the column temperature was 30°C. 
2.4 Analytical Solutions 
2.4.1 Preparation of standard solution 
50.0 mg of Flucytosine standard was taken 
into a 100 ml volumetric flask. 60 ml Purified water 
was added and dissolved with help of ultrasonic bath 
for 10 minutes and mix thoroughly until it dissolves 
and then volume with purified water up to 100 ml 
and mix. 10 ml of this solution was diluted to 100 ml 
with Purified water and mix well. Final concentration 
set for 0.05 mg/ml. 
2.4.2 System Suitability Solution 
Weigh accurately about 5.0 mg of 
Fluorouracil CRS and transfer it into 100 ml Clean 
and dried volumetric flask. Add 50-60 ml of Purified 
water and sonicate for 10 minutes and mix 
thoroughly until it dissolves, and then volume with 
Purified water up to 100 ml and mix. Take 10 ml of 
this solution and 10 ml of the standard solution into a 
50 ml clean and dried volumetric flask, then volume 
with Purified water up to 50 ml and mix well. 
Final concentration for Flucytosine and fluorouracil 
was 0.01 mg/ml respectively. 
2.4.3 Preparation of Sample solution 
Pipette 5 ml of Flucytosine intravenous 
infusion into a 100 ml Clean and dried volumetric 
flask, add 50–60 ml of purified water & shake. Make 
volume up to 100 ml with the same and mix well. 
Concentration of this solution was 0.5 mg/ml. This 
solution will be used for Test solution for 
determination of known impurity (Fluorouracil) and 
any other unknown impurities. 
10 ml of this solution was diluted to 100 ml with 
purified water and mix well for assay preparation for 
determination of Flucytosine (0.05 mg/ml). All 
solution was filtered with 0.20 μm membrane disk 
filters (PALL).  
2.5 Method Validation 
2.5.1 Results of forced degradation studies 
(Specificity) 
Specificity is the ability of the method to 
measure the analyte response in the presence of its 
potential impurity. The specificity of the developed 
HPLC method for Flucytosine was carried out in the 
presence of its impurity namely Fluorouracil. Stress 
studies were performed for Flucytosine bulk drug to 
provide an indication of the stability indicating 
property and specificity of the proposed method. 
Intentional degradation was attempted to stress 
conditions of sunlight exposure and oxidation (10.0 
% H2O2) and Thermal degradation was carried out 
heat at 80°C and was taken sample after 2 hours, 4 
hours, 6 hours and 8 hours to evaluate the ability of 
the proposed method to separate Flucytosine from its 
degradation products. Peak purity test was carried out 
of Flucytosine peak by using PDA detector in stress 
samples. Assay studies were carried out of stress 
samples against qualified Flucytosine reference 
standard. Assay was also calculated for Flucytosine 
samples by spiking Fluorouracil at the specification 
level (i.e., 0.5%). 
2.5.2 Precision 
The precision of the assay method was 
evaluated by carrying out six independent assays of 
Flucytosine test samples against a qualified working 
standard and calculate the % R.S.D of assay. The 
precision of the related substances method was 
checked by injecting six individual preparations of 
Flucytosine (0.5 mg mL-1) spiked with 0.5 % 
Fluorouracil with respect to Flucytosine analyte 
concentration. % R.S.D of area for Fluorouracil was 
calculated. The intermediate precision of the method 
was also evaluated using different analyst and 
different instrument in the same laboratory. 
2.5.3 Limit of detection (LOD) and Limit of 
Quantification (LOQ) 
The detection limit of an individual 
analytical procedure is the lowest amount of analyte 
in a sample that can be detected but not necessarily 
quantitated as an exact value. The quantitation limit 
of an individual analytical procedure is the lowest 
amount of analyte in a sample that can be 
quantitavely determined with suitable precision and 
accuracy. The quantitation limit is a parameter of 
quantitative assays for low levels of compounds in 
sample matrices, and is used particularly for the 
determination of Impurities and/or degradation 
products. The limit of detection (LOD) and limit of 
quantitation (LOQ) were separately determined at a 
signal to noise ratio (S/N) of 3 and 10. 
2.5.4 Linearity 
Linearity test solutions for the assay method 
were prepared from Flucytosine stock solutions at six 
concentration levels from 10% to 150% of assay 
analyte concentration (10%, 30%, 50%, 80%, 100%, 
120%, 150%). The peak area verses concentration 
data was treated by least squares linear regression 
analysis. Linearity test solutions for the related 
substance method were prepared by dilution of stock 
solution to the required concentrations. The solutions 
were prepared at eleven concentration levels from 
LOQ to 150% of specification level (1.0%, 2%, 5%, 
8%, 10%, 20%, 50%, 80%, 100%, 120% and 
150%)for specific impurity (Fluorouracil) and 
thirteen concentration levels from LOQ to 1% of 
specification level (0.008%, 0.01%, 0.02%, 0.04 %, 
0.06%, 0.08%, 0.1%, 0.2%, 0.4%, 0.5%, 0.6%, 0.8% 
and 1.0%) for Flucytosine. Above test were carried 
out of 3 consecutive days for Assay and 2 
consecutive days for related substances method. The 
% RSD value for the Slope and Y-intercept of the 
calibration curve was calculated. 
2.5.5 Accuracy 
The accuracy of the assay method was 
evaluated in triplicate at three concentration levels 
80%,100% and 120 % of sample solution 
concentration (0.05 mg mL-1) .The percentage of 
recoveries was calculated from the Slope and Y- 
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intercept of the calibration curve obtained in the 
linearity study. The accuracy study of impurities was 
carried out in triplicate at 80%, 100%, 120 % of 
specification level (0.5%) to the Flucytosine analyte 
concentration (50μg mL-1). The percentages of 
recoveries for impurities were calculated from the 
slope and Y- Intercept of the calibration curve. 
2.5.6 Range 
Data generated in linearity, precision and 
accuracy was considered for establishing the range of 
the analytical method. 
2.5.7 Robustness 
To determine the robustness of the 
developed method, experimental conditions were 
deliberately altered and the resolution between 
Flucytosine and specific impurity (Fluorouracil) was 
recorded. The flow rate of the mobile phase was 
1.0mL min-1.To study the effect of flow rate on the 
resolution, flow was changed by 0.2 units from 0.8 to 
1.2 mL min-1. The effect of the column temperature 
on resolution was studied at 25°C and 35°C instead 
of 30°C. The effect of the percentage organic strength 
on resolution was studied by varying Methanol by -5 
to + 5 % while other mobile phase components were 
held constant as stated in Chromatographic 
conditions. 
2.5.8 Solution stability 
The solution stability of Flucytosine in the 
assay method was carried out by leaving both the 
solutions of sample and reference standard in tightly 
capped volumetric flasks at room temperature and at 
4°C for 48 hours. The solution stability of 
Flucytosine and its impurities in the related substance 
method was carried out by leaving spiked sample 
solution in tightly capped volumetric flasks at room 
temperature for 48 hours. Content of specific 
impurity (Fluorouracil) was determined after 48 
hours. The mobile phase stability was also carried out 
for 48 hours by injecting the freshly prepared sample 
solutions. Content specific impurity (Fluorouracil) 
was checked in the test solutions. 
 
3. Results and Discussion 
3.1 Optimization of Chromatographic conditions: 
The main objective of chromatographic 
method is to separate Flucytosine from specific 
impurity (Fluorouracil). The chromatographic 
separation was achieved on an Hichrom C18, 250 
mm X 4.6 mm I.D with 5μ particles column, using 
mixture of Water and Methanol (95:5v/v) as a mobile 
phase. The flow rate of the mobile phase was 1.0 mL 
min-1, at 30°C column temperature, the peak shape 
of the Flucytosine was found to be symmetrical. In 
optimized chromatographic conditions of Flucytosine 
and specific impurity (Fluorouracil) separation was 
achieved with resolution greater than 4 and retention 
times were about 4.0 and 4.8 (Figure 6). 
 
3.2 Results of forced degradation studies 
(Specificity) 
Degradation was not observed in 
Flucytosine sample when subjected to stress 
conditions like sunlight. Significant degradation was 
noted in thermal study. Degradation was observed in 
oxidative conditions and in thermal degradation at 
80°C for 2, 4, 6 and 8 hour’s interval (Figure 7). 
Table-1 shows the degradation of Flucytosine by 
80°C at analytical concentration and produce specific 
impurity (Fluorouracil) which indicates a linear 
degradation at a linear Time interval (2, 4, 6, 8 Hours 
of study). Thus during product development, it is 
very much important to set the sterilization 
temperature to maintain the limit of specific impurity 
(fluorouracil) under the limit stated for finished 
product. Peak purity test results confirmed that the 
Flucytosine peak is homogenous in stress samples. 
 
Table 1: Linearity Degradation of Flucytosine by 
Thermal Degradation Study 
Thermal Degradation study  
Hours 
Peak Area (Specific Impurity 
(Fluorouracil) 
2 3082 
4 4442 
6 5838 
8 7288 
Slope 700.7 
y-intercept 1659 
Correlation coefficient, r 0.9999 
Figure 2: Linearity Degradation of Flucytosine by 
Thermal Degradation Study 
 
3.3 Precision 
System Precision was performed by 
replicate injections (n=6) of the standard solution at 
100% of the sample concentration and calculating the 
% RSD of the measured area, theoretical plates and 
tailing factor and the Resolution solution of 
Flucytosine and Fluorouracil. Table-2 shows the 
Resolution Solution Data which indicates the 
resolution is greater than 4.0 and Relative retention 
time is 1.2. Table-3 shows the system precision data 
from Standard solution. From the data it was 
observed that the % RSD of Retention time and Area 
was 0.020 and 0.223 respectively which was well 
within the acceptance limit of 2.0%. Hence the 
system was precise. 
 
Table 2: System Suitability Study-01 
Peak Name. Retention Time RRT Resolution  Tailing Factor Theoretical Plate 
Flucytosine 4.041 --- --- 1.42 16937 
Fluorouracil 4.781 1.2 5.85 1.29 20213 
 
Table 3: System Suitability Study-02 
Determination Retention Time Area Tailing Factor Theoretical Plate 
1 4.040 1926190 1.44 16520 
2 4.041 1924821 1.41 17265 
3 4.040 1931668 1.43 16818 
4 4.039 1926977 1.41 17293 
5 4.040 1935910 1.43 16773 
6 4.041 1932241 1.41 17158 
Mean (n=6) 4.040 1929634 1.42 16971 
Standard Deviation 0.001 4299.012 --- --- 
% Relative Standard Deviation (RSD) 0.020 0.223 --- --- 
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The %RSD of assay of Flucytosine during the assay method precision study was 0.60% and the %RSD 
for the area of Flucytosine and Specific impurity (Fluorouracil) in related substances method precision study 
was within 1.0 %. (Table 4-5) 
            Table 4: Method Precision of Flucytosine in the Assay method Validation 
Sample 
Number 
Theoretical conc. of Flucytosine 
(mg/ml) 
Determined conc. of Flucytosine 
(mg/ml) 
% of 
Recovery 
Sample-1 0.0504 0.0509 101.12 
Sample-2 0.0504 0.0503 99.97 
Sample-3 0.0504 0.0505 100.37 
Sample-4 0.0504 0.0510 101.25 
Sample-5 0.0504 0.0510 101.23 
Sample-6 0.0504 0.0511 101.41 
Mean (%) 100.89 
Standard Deviation 0.58 
% Relative Standard Deviation 0.57 
 
             Table 5: Spiked Sample Method Precision Recovery for Related Substances  
Sample Number Determined conc. of Fluorouracil (ppm) Area % of Recovery 
Sample-1 2.72120 163369 101.16 
Sample-2 2.71959 163273 101.10 
Sample-3 2.72820 163779 101.42 
Sample-4 2.73465 164171 101.66 
Sample-5 2.72981 163878 101.48 
Sample-6 2.72847 163798 101.43 
Mean (%) 101.38 
Standard Deviation 0.209 
% Relative Standard Deviation 0.207 
 
Sample Number Determined conc. of Flucytosine (ppm) Area % of Recovery 
Sample-1 0.9992 40546 99.56 
Sample-2 1.0106 41011 100.70 
Sample-3 0.9909 40210 98.73 
Sample-4 0.9896 40157 98.60 
Sample-5 0.9861 40020 98.26 
Sample-6 0.9928 40289 98.92 
Mean (%) 99.13 
Standard Deviation 0.882 
% Relative Standard Deviation 0.890 
 
3.4 Limit of detection (LOD) and Limit of 
Quantification (LOQ) 
The limit of detection of specific impurity 
(Fluorouracil) and Flucytosine was achieved at 
0.01μg mL-1 each for 20 μL injection volume. The 
limit of quantification of Flucytosine and specific 
impurity (Fluorouracil) is 0.025 μg mL-1 and 0.04 μg 
mL-1. Table 6 shows the precision at the LOQ 
concentrations for Flucytosine and Fluorouracil at 
0.2% and 0.5% of specification level to Flucytosine 
analyte concentration respectively and %RSD 
obtained was 1.99% and 1.60% respectively. 
It is also based on signal-to-noise ratio and it 
was observed that the Signal –to- Noise ratio of 
Flucytosine is 12.0 at 0.04 ppm and 11.1 for 
Fluorouracil at 0.025 ppm at 0.2% and 0.5% of 
specification level to Flucytosine Analyte 
Concentration 0.5mg/ml. So the quantitation limit 
was established as 0.04 ppm (0.008%) for 
Flucytosine and 0.025 ppm (1.0%) for Fluorouracil. 
 
Table 6: LOQ precision of Flucytosine and Fluorouracil 
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Injection 
No. 
Peak area 
of 
Flucytosine 
Signal to noise 
ratio of Flucytosine 
peak 
Peak area of 
Fluorouracil 
Signal to noise 
ratio of 
Fluorouracil peak 
1 1680 11.5 1709 10.2 
2 1738 11.5 1739 10.0 
3 1748 13.8 1691 12.1 
4 1737 12.3 1680 10.7 
5 1700 11.0 1711 12.1 
6 1776 11.9 1661 11.2 
Mean 1729 12.0 1698 11.1 
Standard Deviation 34.50 NA 27.24 NA 
% Relative Standard Deviation 1.99 NA 1.60 NA 
3.5 Linearity 
The linearity calibration plot for the assay 
method was obtained over the calibration ranges 
tested, i.e. 5–75 μg mL-1 and correlation coefficient 
obtained was greater than 0.999. Table-7 shows the 
result that an excellent correlation existed between 
the peak area and concentration of the analysis. 
Linear calibration plot for the related substances 
method was obtained over the calibration ranges 
tested i.e. 0.008% to 1.0% for Flucytosine and 1% to 
150.0 % for specific impurity (Fluorouracil) spiked 
with 0.2% of Flucytosine and 0.5 % Fluorouracil 
respect to Flucytosine analyte concentration (0.5 mg 
mL-1). Table, 8-9 shows the correlation coefficient 
obtained greater than 0.99. Linearity was checked for 
the related substances method over the same 
concentration ranges. The above results shown that 
an excellent correlation existed between the peak 
areas and the concentrations of Flucytosine and 
Fluorouracil. 
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Table 7: Linearity test of Flucytosine Standard 
solution 
% Level Concentration (%) Peak Area 
10 10 200259 
30 30 577312 
50 50 966184 
80 80 1527238 
100 100 1894551 
120 120 2284420 
150 150 2859224 
Slope 18953 
y-intercept 10670 
Correlation coefficient, r 1.000 
Figure 3: Linearity test of Flucytosine Standard 
solution 
 
Table 8: Linearity for Flucytosine (0.2% of Analyte 
concentration 0.5 mg/ml)   
Level Concentration 
(ppm) 
Nominal 
Conc (%) 
Peak 
Area 
1 0.040 0.008 1769 
2 0.050 0.01 2159 
3 0.100 0.02 4048 
4 0.200 0.04 8065 
5 0.300 0.06 11993 
6 0.400 0.08 16080 
7 0.500 0.1 20397 
8 1.000 0.2 40813 
9 2.000 0.4 81097 
10 3.000 0.6 112970 
11 4.000 0.8 150743 
12 5.000 1.0 187500 
Correlation coefficient 0.9996 
SLOPE 40569 
y-intercept 1288.4 
LOD (ppm) 0.01 
LOQ (ppm) 0.04 
Figure 4: Linearity for Flucytosine (0.2% of 
Analyte concentration 0.5 mg/ml)   
 
 
 
Table 9: Linearity for Fluorouracil (0.5% of 
Analyte concentration 0.5 mg/ml)   
 
Level Conc. 
(ppm) 
Nominal 
Conc. (%) 
Peak Area 
1 0.0320 5 5955 
2 0.025 1 1530 
3 0.050 2 3197 
4 0.125 5 7986 
5 0.200 8 13023 
6 0.250 10 16087 
7 0.500 20 32533 
8 1.250 50 80106 
9 2.000 80 128017 
10 2.500 100 162903 
11 3.000 120 191604 
12 3.750 150 242018 
Correlation coefficient 0.99995 
y-intercept 14.264 
SLOPE 64005 
LOD (ppm) 0.01 
LOQ (ppm) 0.025 
 
Figure 5: Linearity for Fluorouracil (0.5% of 
Analyte concentration 0.5 mg/ml)   
 
 
3.6 Accuracy 
The percentage recovery of Flucytosine in 
bulk drug samples was ranged from 99.5 to 
100.15%.The percentage recovery of Flucytosine 
(0.2% of specification level to Flucytosine Analyte 
Concentration 0.5 mg/ml) varied from 99.35% to 
101.25% and specific impurity i.e. Fluorouracil 
(0.2% of specification level to Flucytosine Analyte 
Concentration 0.5 mg/ml) in Flucytosine IV Infusion 
varied from 98.78% to 101.13%. (Table 10-12). The 
HPLC chromatograms of unspike standard solution, 
spike sample of Flucytosine and Fluorouracil at 0.2% 
and 0.5% of specification level to Flucytosine 
Analyte concentration (0.5 mgml
-1
) respectively in 
bulk drug samples are shown in Figure 8. 
Table 10: Accuracy of Flucytosine (Assay) 
Sample 
No 
Spiked 
level (%) 
Theoretical conc. of 
Flucytosine (mg/ml) 
Determined conc. of 
Flucytosine (mg/ml) 
% of 
Recovery 
Mean (%) 
and RSD 
1 80 0.04020 0.0399 100.33 
100.07 
0.08 
2 80 0.04020 0.0399 100.04 
3 80 0.04020 0.0398 100.07 
4 100 0.05025 0.0496 99.63 
99.55 
0.09 
5 100 0.05025 0.0493 99.56 
6 100 0.05025 0.0497 99.45 
7 120 0.06030 0.0603 100.00 
100.15 
0.16 
8 120 0.06030 0.0603 100.05 
9 120 0.06030 0.0604 100.16 
Grand average (%) 99.92 
Pooled RSD 0.326 
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Table 11: Accuracy of Flucytosine (0.2% of specification level to Flucytosine Analyte Concentration) 
Sample 
No 
Spiked 
level (%) 
Theoretical conc. of 
Flucytosine (ppm) 
Determined conc. of 
Flucytosine (ppm) 
% of 
Recovery 
Mean (%) 
and RSD 
1 50 0.5 0.5010 100.20 
99.79 
0.37 
2 50 0.5 0.4985 99.69 
3 50 0.5 0.4974 99.48 
4 100 1.0 1.0258 102.58 
101.25 
1.68 
5 100 1.0 0.9933 99.33 
6 100 1.0 1.0183 101.83 
7 200 2.0 2.0144 100.72 
99.35 
1.59 
8 200 2.0 1.9938 99.69 
9 200 2.0 1.9524 97.62 
Grand average (%) 100.13 
Pooled RSD 1.35 
Table 12: Accuracy of Fluorouracil (0.5% of specification level to Flucytosine Analyte Concentration) 
Sample 
No 
Spiked 
level (%) 
 Theoretical conc. of 
Fluorouracil (ppm) 
Determined conc. of 
Fluorouracil (ppm) 
% of 
Recovery 
Mean and  
% RSD 
1 80 2.0 1.9914 99.57 
99.64 
0.059 
2 80 2.0 1.9936 99.68 
3 80 2.0 1.9932 99.66 
4 100 2.5 2.5235 100.94 
101.13 
0.18 
5 100 2.5 2.5288 101.15 
6 100 2.5 2.5328 101.31 
7 120 3.0 2.9403 98.01 
98.78 
0.679 
8 120 3.0 2.9742 99.14 
9 120 3.0 2.9760 99.20 
Grand average (%) 99.85 
Pooled RSD 0.41 
 
3.7 Range 
The specified range is normally derived 
from linearity studies and depends on the intended 
application of the procedure. It will be established by 
confirming that the analytical procedure provides an 
acceptable degree of linearity, accuracy, precision 
when applied to samples containing amounts of 
analyte within the extremes of the specified range of 
the analytical procedure. The minimum specified 
range should be considered for the assay of 
Flucytosine normally from 80 to 120 percent of the 
test concentration (0.05 mg/ml) and for Relative 
substances method, 80% to 120% and 0.1% to 0.4% 
of specification level to Flucytosine Analyte 
Concentration for Fluorouracil and Flucytosine 
respectively. (Table: 13-14) 
 
Table 13: Range Study (Assay Method) 
Parameter Concentration Range Acceptance Limit Result 
Linearity 10% to 150% R NLT 0.995 R= 1.0000 
Method Precision 
100% of Sample 
Solution 
% RSD = NMT 2.0 
 Assay 98% to 102% 
% RSD is 0.32%, Assay 
99.85% to 100.57% 
Intermediate 
Precision 
100% of Sample 
Solution 
% RSD of two analyst NMT 2.0, 
Assay 98% to 102%, %RSD of 
Assay NMT 2.0 
% RSD of two analyst 
0.67, Assay: 99.83.% – 
100.10%, % RSD of 
Assay: 0.11 
Accuracy 
80% to 120% of Sample 
solution Concentration. 
%Recovered= 98 % to 102% 99.55 -100.15 
 
Table 14: Range Study (Related Substances Method) 
Parameter Concentration Range Acceptance Limit Result 
Linearity at 
LOQ 
concentration 
0.008% to 1% for Flucytosine at LOQ 
level 
1% to 150% for Fluorouracil at LOQ 
Level 
R NLT 0.99 
Flucytosine: 0.9996 
Fluorouracil: 0.99995 
Method 
Precision 
100% and 0.2% of specification level to 
Flucytosine Analyte Concentration for 
Fluorouracil and Flucytosine 
respectively 
% RSD = NMT 
5.0 
% Recover 90% 
to 110% 
Fluorouracil: % RSD is 
0.20%, Assay 101.10% to 
101.66% & Flucytosine: % 
RSD is 0.89%, Assay 
98.26% to 100.70% 
Intermediate 
Precision 
100% and 0.2% of specification level to 
Flucytosine Analyte Concentration for 
Fluorouracil and Flucytosine 
respectively 
% RSD of two 
analyst NMT 
2.0 Assay 90% to 
110% 
%RSD of Assay 
NMT 2.0 
Fluorouracil: % RSD of two 
analyst 0.50, Assay: 99.54.% 
– 102.57%, % RSD of Assay: 
1.14 
Flucytosine: % RSD of two 
analyst 0.78, Assay: 97.98.% 
– 101.60%, % RSD of Assay: 
1.83 
Accuracy 
80% to 120% and 0.1% to 0.4% of 
specification level to Flucytosine 
Analyte Concentration for Fluorouracil 
and Flucytosine respectively 
%Recovered= 98 
% to 102% 
Fluorouracil: 98.79 – 
101.13 
Flucytosine: 99.35 – 101.25 
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3.8 Robustness 
In all the deliberate varied chromatographic 
conditions (flow rate, composition of organic solvent 
& column temperature) the resolution between 
critical pair, i.e. Flucytosine and Fluorouracil was 
greater than 3.5, illustrating the robustness of the 
method. (Table 15) 
 
Table 15: Data of System suitability & % Assay (Robustness study) for Assay Method  
Condition Resolution 
Area of 
Standard 
%RSD of 
Area 
% Recovery 
Acceptance Limit 
AMV: 98.0% to 102.0% 
RSMV: 90.0% to 110.0% 
Analyst 1 4.61 1942112  100.89 
Analyst 2  5.82 1952057 0.15 99.93 
Temperature 25°C 5.55 1937803 0.58 99.14 
Temperature 35°C  4.69 1932078 0.08 99.20 
Flow Rate 0.8 ml/min  5.30 2404806 0.12 99.55 
Flow Rate 1.2 ml/min 6.36 1603728 0.15 99.19 
Organic + PW (10+90) 3.78 1928106 0.32 100.19 
Organic + PW (0+100) 7.30 1925538 0.20 100.17 
Mean % 99.78 
Standard Deviation 0.62 
% Relative Standard Deviation 0.62 
Data of System suitability & % Assay (Robustness study) for Related Substances Method 
Condition Resolution 
Area of 
Standard 
%RSD of 
Area 
% Recovery 
Acceptance Limit 
90.0% to 110.0% 
Analyst 1 6.78 1917641 0.22 
Flucytosine 99.15 
Fluorouracil 100.24 
Analyst 2 5.90 1929918 0.12 
Flucytosine 100.25 
Fluorouracil 99.53 
Temperature 25°C 6.88 1928358 0.10 
Flucytosine 99.20 
Fluorouracil 98.87 
Temperature 35°C 5.96 1932417 0.37 
Flucytosine 94.66 
Fluorouracil 98.67 
Flow Rate 0.8 ml/min 6.71 2425472 0.17 
Flucytosine 99.19 
Fluorouracil 99.45 
Flow Rate 1.2 ml/min 6.36 1612275 0.08 
Flucytosine 98.22 
Fluorouracil 99.26 
Mean % 98.89 
Standard Deviation 1.45 
% Relative Standard Deviation 1.46 
 
3.9 Solution stability 
The %RSD of assay of Flucytosine during 
solution stability experiment was within 0.2%. No 
significant changes were observed in the content of 
impurities namely specific impurity (Fluorouracil) 
during the solution stability and mobile phase 
stability experiments when performed using the 
related substance method. The solution stability and 
mobile phase stability experiment data confirms that 
the sample solution and mobile phases used during 
the assay and the related substance determination 
were stable for 48 hours. 
Table 16: Solution Stability: 
Time Interval % Assay Difference in % Assay initial 
Initial Standard 100.00 --- 
After 48 Hrs at RT Standard 100.14 0.14 
After 48 Hrs at 2-8 Standard 100.16 0.16 
Initial Sample 100.06 --- 
After 72 Hrs at RT Sample 99.63 0.43 
After 72 Hrs at 2-8°C Sample 100.06 0.00 
Mean % 100.00 
Standard Deviation 0.19 
% Relative Standard Deviation 0.19 
 
Figure 6: Representative Chromatogram of Flucytosine and specific impurity (Fluorouracil) at 
concentration 0.01 mg/ml respectively. 
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Figure 7: Thermal degradation at 80°C for 2, 4, 6 and 8 hour’s interval 
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Figure-8: HPLC chromatograms of unspike standard solution 
 
Flucytosine 0.2% + Fluorouracil 0.5% of specification level to Flucytosine Analyte concentration 
 
 
Fluorouracil 0.5% of specification level to Flucytosine Analyte concentration (0.5 mg/ml) 
 
4. Conclusion 
The HPLC method developed for quantitative 
and related substance determination of Flucytosine is 
linear, accurate, precise, rapid and specific. The 
method was fully validated showing satisfactory data 
for all method validation parameters tested. The 
developed method is stability indicating and can be 
conveniently used for quality control to determine the 
related substance and assay in regular Flucytosine 
product development, production and stability 
samples. 
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